A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

Completed · Phase 2

Conditions studied: LMNA-Related Dilated Cardiomyopathy

In brief

This is a Phase 2 pilot study, involving a 48-week treatment period, designed to test the effectiveness of investigational study drug ARRY-371797 in treating patients with symptomatic genetic dilated cardiomyopathy due to a lamin A/C gene mutation, and to further evaluate the drug's safety. Approximately 12 patients from the US will be enrolled in this study.

Key facts

Study ID

NCT02057341

Run by

Pfizer

People needed

12

Starts

2014-02-01

Expected to finish

2016-05-01

Last updated by the study team

2020-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States
• University of Colorado School of Medicine — Aurora, Colorado, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• The Ohio State University — Columbus, Ohio, United States
• Meriter Wisconsin Heart — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.